When AI is directly integrated into the EHR it not only improves efficiency but also ensures that patient data remains secure within the same trusted system. The post EHRs Are Overloading Mental Health Clinicians — Can AI Save the Day? appeared first on MedCity News.
President-elect Donald Trump’s choice to run the sprawling government agency that administers Medicare, Medicaid, and the Affordable Care Act marketplace — celebrity doctor Mehmet Oz — recently held broad investments in health care, tech, and food companies that would pose significant conflicts of interest. Oz’s holdings, some shared with family, included a stake in UnitedHealth…
The $65 million acquisition will grow the virtual care giant’s lineup of preventative services.
Facility will initially house approximately 40 principal investigators, alongside 250 graduate students, postdoctoral fellows, computer scientists, and support staff
This brief considers how default enrollment into Medicare Advantage might work, potential challenges with this approach, and implications for beneficiaries, insurers, providers, agents and brokers, and the federal budget.
Controversial figure Robert F. Kennedy has been announced as Trump’s HHS Secretary nominee
Oral contraceptives are the most commonly used method of reversible contraception in the U.S. In July 2023, the FDA approved Opill, the first daily oral contraceptive pill to become available over the counter (OTC) without a doctor’s prescription. This issue brief provides an overview of OTC oral contraceptives and laws and policies related to insurance…
The Glp-1 battle heats with new preliminary data from Eli Lilly showing that patients using its weight loss drug Zepbound lost more weight on average in 72 weeks than those on Novo Nordisk’s Wegovy. The post Video: Battle of the Bulge – Wegovy vs. Zepbound appeared first on MedCity News.
Novo Nordisk’s amycretin is a single molecule designed to bind to two targets to spark weight loss — a different approach than some of the pharma giant’s other efforts to develop next-generation obesity drugs. Analysts say the lack of details safety and tolerability details make it difficult to fully assess the preliminary Phase 1b/2a results….
Laboratory construction has waned in the past two years due to the end of the pandemic and an economic slowdown, according to a new report from CBRE. The firm predicts in-progress lab construction will decline to pre-pandemic levels by 2026. The post CBRE Report: Post-Pandemic Slowdown Now Evident in Oversupply of Biotech Labs appeared first…